Sir, Bevacizumab (Avastin) in central retinal vein occlusion I read the article by Shah and Shah 1 with great interest. I congratulate the authors for evaluating the effects of early single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation laser in central retinal vein occlusion (CRVO) with macular oedema.
I would like to share my experience of single early intravitreal injection of bevacizumab in two cases of macular oedema secondary to central retinal vein occlusion. Both patients had only a single intravitreal injection of bevacizumab within a week of onset of symptoms, without the need for panretinal photocoagulation or macular grid lasers.
Case reports
Case 1 A 23-year old male presented with left eye CRVO and macular oedema and a visual acuity (VA) of 6/24. He received a single intravitreal injection of Avastin at 6 days after the onset of symptoms. He was seen 11 days later with VA of 6/6 and OCT showing resolution of macular oedema. Seventeen months later, his left VA remains 6/4.8 (unaided) and no macular oedema on OCT. He did not need any further intervention after the first injection.
Case 2
A 79-year old male presented with left CRVO with macular oedema and a VA of 2/60. He had neovascular glaucoma in the other eye secondary to CRVO. When seen 3 days after the onset of his symptoms in the left eye, he underwent an intravitreal injection of Avastin the same day. VA returned to 6/9 in 2 weeks. Twenty one months later, he still maintains a VA of 6/9 unaided and has no macular oedema on OCT. 
Comment
Both patients did not need any further injections after the first one, nor did they receive extensive retinal lasers as was the case in the article by Shah and Shah. 1 I agree, larger studies are needed to substantiate the results, but until then it is best to treat on a case by case basis.
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Case report
A 52-year-old Caucasian man with metastatic RCC reported decreasing visual acuity in both eyes. He had been taking sunitinib 50 mg per day for 3 weeks.
Examination revealed an uncorrected visual acuity of 6/12 on both eyes and best-corrected visual acuity of 6/6 ( þ 2.0). A widespread serous detachment of the retina was present in both eyes (Figures 1a and b) . Optical coherence tomography (OCT) revealed a bilateral neurosensory retinal detachment and a diffuse oedema (Figures 1c and d ). The treatment with sunitinib was discontinued. Two weeks later, the patient presented with an uncorrected visual acuity of 6/6 on both eyes. OCT showed a complete bilateral resolution of the neurosensory retinal detachment and retinal oedema (Figures 1e and f) . 
